CRBU · Caribou Biosciences, Inc.

Caribou Biosciences Inc Is A Clinical-Stage Clustered Regularly Interspaced Short Palindromic Repeats (Crispr) Genome-Editing Biopharmaceutical Company Dedicated To Developing Transformative Therapies For Patients With Devastating Diseases. The Company Is Focused On Advancing Two Clinical-Stage Allogeneic Car-T Cell Therapy Product Candidates For The Treatment Of Patients With Hematologic Malignancies: Vispacabtagene Regedleucel And Cb-011. It Operates In One Reportable Segment, Which Is The Business Of Developing Allogeneic Car-T Cell Therapies. Geographically, It Operates In The United States And The Rest Of The World, Of Which The United States Derives The Maximum Revenue.